NBRV Stock Summary

• With a price/sales ratio of 420.89, Nabriva Therapeutics plc has a higher such ratio than 99.37% of stocks in our set.
• With a year-over-year growth in debt of 4,005.74%, Nabriva Therapeutics plc's debt growth rate surpasses 98.77% of about US stocks.
• As for revenue growth, note that NBRV's revenue has grown -68.27% over the past 12 months; that beats the revenue growth of merely 2.11% of US companies in our set.
• Stocks that are quantitatively similar to NBRV, based on their financial statements, market capitalization, and price volatility, are KDMN, GERN, ADVM, PRTA, and NYMX.
• Visit NBRV's SEC page to see the company's official filings. To visit the company's web site, go to www.nabriva.com.